KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Treatment mechanism and research progress of bevacizumab for glioblastoma.

Xinliang Liu, Zhigang Chen, Pengwei Yan, Tao Yang, Dan Zong, Wenjie Guo, Xia He

Am J Cancer Res 15(4) 1874-1901

PMID40371151
PMCIDPMC12070100
DOI10.62347/RNUE7193
发表日期2025-05-15
摘要

摘要

Hypervascularization is a notable pathological hallmark of glioblastoma (GBM). Bevacizumab (Bev) remains the sole antiangiogenic agent approved by the U.S. Food and Drug Administration (FDA) for GBM treatment. The approval for this indication was supported by several phase II studies demonstrating that Bev significantly improved progression-free survival and the best imaging response in patients with recurrent GBM. Three large phase III randomized controlled trials reported that Bev did not significantly extend overall survival (OS). Nevertheless, Bev has been shown to delay the deterioration of patients' quality of life by postponing tumor progression. This review synthesizes findings from recent investigations exploring Bev in combination with targeted therapies, immunotherapy, or reirradiation. Additionally, this review discusses dosing regimens, administration, treatment failure patterns, third-line therapeutic applications, and prognostic markers of Bev. By synthesizing current evidence, this review aims to inform clinical decision-making for neuro-oncology clinicians.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。